Paris, France et Camberley, Royaume-Uni – 13 janvier 2021 – Novacyt (EURONEXT GROWTH : ALNOV ; AIM : NCYT), spécialiste mondial du diagnostic clinique, annonce avoir été informée le 12 janvier 2021 que, au 11 janvier 2021, la participation de BlackRock Inc. dans Novacyt sur la base du capital et des droits de vote est
Visit PageYear: 2021
Holdings in Company
Paris, France and Camberley, UK – 13 January 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it was notified on 12 January 2021 that, as at 11 January 2021 BlackRock Inc.’s holding in the Company on a voting and capital basis is 2.95% (2,085,368 shares). http://novacyt.com/wp-content/uploads/2021/01/Novacyt-BlackRock-holdings-13.01.2021-ENGLISH.pdf
Visit PageExecutive Management and Proposed Board Changes
Paris, France and Camberley, UK – 5 January 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that James McCarthy has been appointed as Chief Financial Officer (CFO), whilst Anthony Dyer has taken on a new role as Chief Corporate Development Officer (CCDO). Both appointments are with immediate effect.
Visit Page